TRANBERG Thermal Therapy System developer Clinical Laserthermia Systems AB (publ) (STO:CLS-B) announced on Thursday that it has received additional orders from ClearPoint Neuro, Inc (Nasdaq:CLPT), a medical device company, valued at approximately SEK7.5m.
These orders are for ClearPoint Prism products as part of ClearPoint Neuro's North American market launch initiated in early June this year. This follows previous orders totaling approximately SEK10.5m received around the turn of the year 2023/2024.
CLS and ClearPoint Neuro aim to develop and commercialize a next-generation, fully integrated laser therapy system for high-precision MRI-guided stereotactic laser ablation in neurosurgery. The integrated product solution offers streamlined workflows for identifying, navigating and positioning sterile laser applicators in target tissues, with MRI-guided monitoring and control of temperature and ablation progress.
Recent strategic steps include obtaining US-FDA 510(k) clearance for ClearPoint Neuro's Prism Bone Anchor Accessory, further strengthening the product offering and expanding the market in the US.
(EUR1=SEK11.19)
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study
Nicox and Glaukos sign exclusive research and licensing option agreement
Creo Medical forms strategic partnership with Micro-Tech via EUR36.7m subsidiary sale
Epitomee Medical's Capsule cleared by FDA for weight management
Eurofins strengthens biopharma testing in US with Infinity Labs acquisition